Ocular Therapeutix Inc (OCUL)
5.00
-0.08
(-1.48%)
USD |
NASDAQ |
Apr 23, 16:00
4.995
0.00 (0.00%)
After-Hours: 20:00
Ocular Therapeutix Cash from Operations (TTM): -70.23M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -70.23M |
September 30, 2023 | -64.74M |
June 30, 2023 | -70.18M |
March 31, 2023 | -60.98M |
December 31, 2022 | -59.60M |
September 30, 2022 | -57.80M |
June 30, 2022 | -57.61M |
March 31, 2022 | -66.79M |
December 31, 2021 | -65.55M |
September 30, 2021 | -56.64M |
June 30, 2021 | -57.32M |
March 31, 2021 | -52.06M |
December 31, 2020 | -53.55M |
September 30, 2020 | -66.78M |
June 30, 2020 | -72.66M |
March 31, 2020 | -77.05M |
December 31, 2019 | -77.58M |
September 30, 2019 | -71.76M |
June 30, 2019 | -63.09M |
March 31, 2019 | -56.14M |
December 31, 2018 | -49.23M |
Date | Value |
---|---|
September 30, 2018 | -45.96M |
June 30, 2018 | -49.47M |
March 31, 2018 | -48.37M |
December 31, 2017 | -50.47M |
September 30, 2017 | -47.70M |
June 30, 2017 | -40.65M |
March 31, 2017 | -39.32M |
December 31, 2016 | -34.00M |
September 30, 2016 | -35.02M |
June 30, 2016 | -37.39M |
March 31, 2016 | -36.12M |
December 31, 2015 | -33.74M |
September 30, 2015 | -30.73M |
June 30, 2015 | -27.37M |
March 31, 2015 | -23.35M |
December 31, 2014 | -20.50M |
September 30, 2014 | -18.33M |
June 30, 2014 | -14.84M |
March 31, 2014 | -13.29M |
December 31, 2013 | -12.64M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-77.58M
Minimum
Dec 2019
-52.06M
Maximum
Mar 2021
-64.31M
Average
-64.74M
Median
Sep 2023
Cash from Operations (TTM) Benchmarks
Assertio Holdings Inc | 49.60M |
CytomX Therapeutics Inc | -56.04M |
EyePoint Pharmaceuticals Inc | 1.875M |
Regeneron Pharmaceuticals Inc | 4.594B |
Cormedix Inc | -38.41M |